Literature DB >> 34280021

MIC Distributions of Routinely Tested Antimicrobials and of Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline for Mycobacterium fortuitum.

Ka Lip Chew1, Sophie Octavia2, Joelle Go1, Siang Fei Yeoh3, Jeanette Teo1.   

Abstract

Entities:  

Keywords:  Mycobacterium fortuitum; bedaquiline; broth microdilution; clofazimine; delafloxacin; eravacycline; rifabutin

Mesh：

Substances：

Year:  2021        PMID： 34280021      PMCID： PMC8448126          DOI： 10.1128/AAC.00593-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Infections due to rapidly growing mycobacteria.

Authors:  Mary A De Groote; Gwen Huitt
Journal:  Clin Infect Dis       Date:  2006-05-11       Impact factor: 9.079

2.  Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates.

Authors:  Su-Young Kim; Seong Mi Moon; Byung Woo Jhun; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Seung Heon Lee; Sung Jae Shin; Shannon H Kasperbauer; Gwen A Huitt; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  MIC Ranges of Quality Control Strain Mycobacterium peregrinum ATCC 700686 against Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline.

Authors:  Matilda Boey; Zhehao Liu; Jeanette Teo; Sophie Octavia; Bintou A Ahidjo; Ka Lip Chew
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 5.948

Review 4.  British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Authors:  Charles S Haworth; John Banks; Toby Capstick; Andrew J Fisher; Thomas Gorsuch; Ian F Laurenson; Andrew Leitch; Michael R Loebinger; Heather J Milburn; Mark Nightingale; Peter Ormerod; Delane Shingadia; David Smith; Nuala Whitehead; Robert Wilson; R Andres Floto
Journal:  Thorax       Date:  2017-11       Impact factor: 9.139

5.  In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens.

Authors:  Ka Lip Chew; Sophie Octavia; Joelle Go; Sally Ng; Yit Er Tang; Patsy Soh; Joy Yong; Roland Jureen; Raymond Tzer Pin Lin; Siang Fei Yeoh; Jeanette Teo
Journal:  J Antimicrob Chemother       Date:  2021-03-12       Impact factor: 5.790

6.  Rapidly growing mycobacteria in Singapore, 2006-2011.

Authors:  S S Tang; D C Lye; R Jureen; L-H Sng; L Y Hsu
Journal:  Clin Microbiol Infect       Date:  2014-11-04       Impact factor: 8.067

7.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

8.  Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore.

Authors:  Albert Y H Lim; Sanjay H Chotirmall; Eric T K Fok; Akash Verma; Partha P De; Soon Keng Goh; Ser Hon Puah; Daryl E L Goh; John A Abisheganaden
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317
  8 in total
  1 in total

1.  In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2022-08-09       Impact factor: 5.938
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.